Abstract
Epigenetics refers to DNA methylation, histone modifications and microRNAs and these epigenetic modifications are extensively investigated as potential biomarkers for cancer. Characterizing genome wide epigenetic changes involved in prostate cancer development and progression will not only identify potential novel therapeutic targets, since some epigenetic modifications are reversible, but also highlight which epigenetic changes can be used as prostate cancer biomarkers. Epigenetic changes are relatively stable and easy to measure in peripheral samples like blood and urine, further highlighting their importance as powerful tools for assessing patient diagnosis and prognosis. In this review, we outline how epigenetic biomarkers have been used for diagnosis, prognosis and for monitoring therapeutic response in prostate cancer. We also review how epigenetic biomarkers may be more sensitive and specific than current prostate cancer serum markers and the possibility that combining different epigenetic modifications may further enhance the diagnostic and prognostic ability of these epigenetic biomarkers. As epigenome wide studies continue to be performed in larger patient cohorts, we will soon identify the epigenetic modifications involved in prostate tumorigenesis with the resultant identification of new therapeutic targets and robust prostate cancer biomarkers.
Karen Chiam and Tanya Kate Day contributed equally to this work.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90
Sakr WA, Grignon DJ, Haas GP, Heilbrun LK, Pontes JE, Crissman JD (1996) Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 30:138–144
Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD (2004) Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11:459–476
Asmane I, Ceraline J, Duclos B, Rob L, Litique V, Barthelemy P et al (2011) New strategies for medical management of castration-resistant prostate cancer. Oncology 80:1–11
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320–1328
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310–1319
Neal DE, Donovan JL (2000) Prostate cancer: to screen or not to screen? Lancet Oncol 1:17–24
Henrique R, Jeronimo C (2004) Molecular detection of prostate cancer: a role for GSTP1 hypermethylation. Eur Urol 46:660–669; discussion 669
Roehrborn CG, Boyle P, Gould AL, Waldstreicher J (1999) Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53:581–589
Schatteman PH, Hoekx L, Wyndaele JJ, Jeuris W, Van Marck E (2000) Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 37:404–412
Djulbegovic M, Beyth RJ, Neuberger MM, Stoffs TL, Vieweg J, Djulbegovic B et al (2010) Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ 341:c4543
Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A (2011) Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 50(Suppl 1):61–75
Bjartell A, Montironi R, Berney DM, Egevad L (2011) Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol 50(Suppl 1):76–84
Roobol MJ, Haese A, Bjartell A (2011) Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol 50(Suppl 1):85–89
Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC et al (2012) Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol 188:1726–1731
Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA et al (2009) ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol 56:275–286
Lin DW, Newcomb LF, Brown EC, Brooks JD, Carroll P, Ziding Feng, Gleave ME, Lance R, Sanda MG, Thompson IM, Wei J, Nelson P (2012) Urinary TMPRSS2: use of ERG and PCA3 to predict tumor volume and Gleason grade in an active surveillance cohort–results from the Canary/EDRN Prostate Active Surveillance Study. J Clin Oncol 30(suppl 5; abstr 2)
Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S et al (2011) Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med 3:94ra72
Dobosy JR, Roberts JL, Fu VX, Jarrard DF (2007) The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 177:822–831
Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ et al (2011) Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 60:753–766
Li LC, Carroll PR, Dahiya R (2005) Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 97:103–115
Schulz WA, Hatina J (2006) Epigenetics of prostate cancer: beyond DNA methylation. J Cell Mol Med 10:100–125
Chan TA, Glockner S, Yi JM, Chen W, Van Neste L, Cope L et al (2008) Convergence of mutation and epigenetic alterations identifies common genes in cancer that predict for poor prognosis. PLoS Med 5:e114
Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome – biological and translational implications. Nat Rev Cancer 11:726–734
Hake SB, Xiao A, Allis CD (2004) Linking the epigenetic ‘language’ of covalent histone modifications to cancer. Br J Cancer 90:761–769
Szyf M, Pakneshan P, Rabbani SA (2004) DNA demethylation and cancer: therapeutic implications. Cancer Lett 211:133–143
Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z et al (2008) DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 68:8954–8967
Brothman AR, Swanson G, Maxwell TM, Cui J, Murphy KJ, Herrick J et al (2005) Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet Cytogenet 156:31–36
Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA (1999) High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 39:166–174
Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R et al (2002) Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 35:58–65
Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM et al (2007) Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 211:269–277
Yang B, Sun H, Lin W, Hou W, Li H, Zhang L et al (2011) Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry. Urol Oncol. 2011 Jun 23. [Epub ahead of print]
Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16:168–174
Miyamoto K, Ushijima T (2005) Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol 35:293–301
Perry AS, Foley R, Woodson K, Lawler M (2006) The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr Relat Cancer 13:357–377
Park JY (2010) Promoter hypermethylation in prostate cancer. Cancer Control 17:245–255
Phe V, Cussenot O, Roupret M (2010) Methylated genes as potential biomarkers in prostate cancer. BJU Int 105:1364–1370
Wu T, Giovannucci E, Welge J, Mallick P, Tang WY, Ho SM (2011) Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. Br J Cancer 105:65–73
Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG et al (2003) Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol 163:923–933
Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS et al (1994) Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A 91:11733–11737
Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G et al (2004) A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 10:8472–8478
Li LC, Okino ST, Dahiya R (2004) DNA methylation in prostate cancer. Biochim Biophys Acta 1704:87–102
Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Li LC et al (2005) Multigene methylation analysis for detection and staging of prostate cancer. Clin Cancer Res 11:6582–6588
Meiers I, Shanks JH, Bostwick DG (2007) Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. Pathology 39:299–304
Febbo PG (2009) Epigenetic events highlight the challenge of validating prognostic biomarkers during the clinical and biologic evolution of prostate cancer. J Clin Oncol 27:3088–3090
Hopkins TG, Burns PA, Routledge MN (2007) DNA methylation of GSTP1 as biomarker in diagnosis of prostate cancer. Urology 69:11–16
Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG (2004) GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 91:540–552
Bastian PJ, Ellinger J, Wellmann A, Wernert N, Heukamp LC, Muller SC et al (2005) Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 11:4097–4106
Roupret M, Hupertan V, Yates DR, Catto JW, Rehman I, Meuth M et al (2007) Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res 13:1720–1725
Baden J, Green G, Painter J, Curtin K, Markiewicz J, Jones J et al (2009) Multicenter evaluation of an investigational prostate cancer methylation assay. J Urol 182:1186–1193
Baden J, Adams S, Astacio T, Jones J, Markiewicz J, Painter J et al (2011) Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay. J Urol 186:2101–2106
Bastian PJ, Palapattu GS, Lin X, Yegnasubramanian S, Mangold LA, Trock B et al (2005) Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 11:4037–4043
Roupret M, Hupertan V, Catto JW, Yates DR, Rehman I, Proctor LM et al (2008) Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer 122:952–956
Bastian PJ, Ellinger J, Heukamp LC, Kahl P, Muller SC, von Rucker A (2007) Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 51:665–674; discussion 674
Woodson K, O’Reilly KJ, Ward DE, Walter J, Hanson J, Walk EL et al (2006) CD44 and PTGS2 methylation are independent prognostic markers for biochemical recurrence among prostate cancer patients with clinically localized disease. Epigenetics 1:183–186
Rosenbaum E, Hoque MO, Cohen Y, Zahurak M, Eisenberger MA, Epstein JI et al (2005) Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 11:8321–8325
Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T (2011) GSTP1 DNA methylation and expression status is indicative of 5-aza-2′-deoxycytidine efficacy in human prostate cancer cells. PLoS One 6:e25634
Horvath LG, Mahon KL, Qu W, Devaney J, Chatfield MD, Paul C et al (2011) A study of methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of response to chemotherapy and prognosis in men with castration-resistant prostate cancer (CRPC). J Clin Oncol 29(suppl):abstr 4603
Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391–400
Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV et al (2008) Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 47:701–706
Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M et al (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435:1262–1266
Barlesi F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P et al (2007) Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 25:4358–4364
Van Den Broeck A, Brambilla E, Moro-Sibilot D, Lantuejoul S, Brambilla C, Eymin B et al (2008) Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res 14:7237–7245
Zhou LX, Li T, Huang YR, Sha JJ, Sun P, Li D (2010) Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy. Asian J Androl 12:171–179
Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ (2008) The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 15:1968–1976
Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gutgemann I et al (2010) Global levels of histone modifications predict prostate cancer recurrence. Prostate 70:61–69
Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M et al (2010) Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. Cancer Epidemiol Biomarkers Prev 19:2611–2622
Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S et al (2009) Global levels of histone modifications predict prognosis in different cancers. Am J Pathol 174:1619–1628
Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G et al (2010) Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704. J Clin Oncol 28:1358–1365
Cai MY, Tong ZT, Zhu W, Wen ZZ, Rao HL, Kong LL et al (2011) H3K27me3 protein is a promising predictive biomarker of patients’ survival and chemoradioresistance in human nasopharyngeal carcinoma. Mol Med 17:1137–1145
Rogenhofer S, Kahl P, Mertens C, Hauser S, Hartmann W, Buttner R et al (2012) Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int 109:459–465
Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA (2003) Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95:661–668
Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA (2007) Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 6:1403–1412
Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629
van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA et al (2007) Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 52:455–463
Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T (2008) EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 122:595–602
Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, Mehra R et al (2007) A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 67:10657–10663
Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA et al (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24:268–273
Deligezer U, Akisik EE, Erten N, Dalay N (2008) Sequence-specific histone methylation is detectable on circulating nucleosomes in plasma. Clin Chem 54:1125–1131
Schwarzenbach H, Hoon DS, Pantel K (2011) Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 11:426–437
Deligezer U, Yaman F, Darendeliler E, Dizdar Y, Holdenrieder S, Kovancilar M et al (2010) Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin Chim Acta 411:1452–1456
Arita A, Niu J, Qu Q, Zhao N, Ruan Y, Nadas A et al (2012) Global levels of histone modifications in peripheral blood mononuclear cells of subjects with exposure to nickel. Environ Health Perspect 120:198–203
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105:10513–10518
Pang Y, Young CY, Yuan H (2010) MicroRNAs and prostate cancer. Acta Biochim Biophys Sin (Shanghai) 42:363–369
Coppola V, De Maria R, Bonci D (2010) MicroRNAs and prostate cancer. Endocr Relat Cancer 17:F1–F17
Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S et al (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59:671–681
Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F et al (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126:1166–1176
Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, Trapman J et al (2012) Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 31:978–991
Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T et al (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128:608–616
Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T et al (2012) MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 130:611–621
Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F et al (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68:6162–6170
Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67:6130–6135
Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S et al (2009) MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 16:206–216
Hagman Z, Larne O, Edsjo A, Bjartell A, Ehrnstrom RA, Ulmert D et al (2010) miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 127:2768–2776
Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K et al (2010) MicroRNAs and cancer: current state and future perspectives in urologic oncology. Urol Oncol 28:4–13
Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ et al (2012) Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 131(3):652–661
Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y et al (2008) Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One 3:e2079
Coolen MW, Stirzaker C, Song JZ, Statham AL, Kassir Z, Moreno CS et al (2010) Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol 12:235–246
Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A et al (2012) Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res 72:616–625
Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S et al (2011) Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 21:1028–1041
Kim SJ, Kelly WK, Fu A, Haines K, Hoffman A, Zheng T et al (2011) Genome-wide methylation analysis identifies involvement of TNF-alpha mediated cancer pathways in prostate cancer. Cancer Lett 302:47–53
Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, Kim IY et al (2011) EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res 17:4523–4530
Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM et al (2011) DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 21:1017–1027
Kron K, Pethe V, Briollais L, Sadikovic B, Ozcelik H, Sunderji A et al (2009) Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One 4:e4830
Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG et al (2012) Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 18:2882–2895
Goering W, Kloth M, Schulz WA (2012) DNA methylation changes in prostate cancer. Methods Mol Biol 863:47–66
Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y et al (2009) Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930–935
Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG et al (2011) Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2:627–637
Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA et al (2011) Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 333:1300–1303
Irizarry RA, Ladd-Acosta C, Wen B, Wu Z, Montano C, Onyango P et al (2009) The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 41:178–186
Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG et al (2011) Increased methylation variation in epigenetic domains across cancer types. Nat Genet 43:768–775
Statham AL, Robinson MD, Song JZ, Coolen MW, Stirzaker C, Clark SJ (2012) Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA. Genome Res 22:1120–1127
Sak A, Stuschke M (2010) Use of gammaH2AX and other biomarkers of double-strand breaks during radiotherapy. Semin Radiat Oncol 20:223–231
Hua S, Kallen CB, Dhar R, Baquero MT, Mason CE, Russell BA et al (2008) Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 4:188
Dryhurst D, McMullen B, Fazli L, Rennie PS, Ausio J (2012) Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression. Cancer Lett 315:38–47
Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, Marquez VE et al (2011) Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer 10:40
Acknowledgements
 This work was supported by grants from the National Health and Medical Research Council (627185; TBM), Cancer Council of South Australia/SAHMRI Beat Cancer Project (APP1030945; TBM), the U.S. Department of Defense Prostate Cancer Training Fellowship (TKD; PC080400), W. Bruce Hall Cancer Council of SA Research Fellowship (TBM), and The Prostate Cancer Foundation of Australia (TKD; YIG03).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Chiam, K., Day, T.K., Bianco-Miotto, T. (2013). Recent Updates on Epigenetic Biomarkers for Prostate Cancer. In: Sarkar, F. (eds) Epigenetics and Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-6612-9_8
Download citation
DOI: https://doi.org/10.1007/978-94-007-6612-9_8
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-6611-2
Online ISBN: 978-94-007-6612-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)